This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brankley, S. M. Articles by Halling, K. C. Search for Related Content PubMed PubMed Citation Articles by Brankley, S. M. Articles by Halling, K. C.

JMD 2006, Vol. 8, No. 2
Copyright © 2006 American Society for Investigative Pathology & Association for Molecular Pathology

The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett’s Esophagus

Shannon M. Brankley^*, Kenneth K. Wang, Aaron R. Harwood^*, Dylan V. Miller^*, Mona S. Legator, Lori S. Lutzke, Benjamin R. Kipp^*, Larry E. Morrison and Kevin C. Halling^*

From the Departments of Laboratory Medicine and Pathology * and Gastroenterology, Mayo Clinic and Foundation, Rochester, Minnesota; and Vysis/Abbott Molecular, Des Plaines, Illinois

The goal of this study was to identify a set of fluorescence in situ hybridization probes for the detection of dysplasia and adenocarcinoma in patients with Barrett’s esophagus. We examined 170 brushing specimens from 138 patients with Barrett’s esophagus or a history of Barrett’s esophagus using fluorescence in situ hybridization with probes to 5p15, 5q21-22, centromere 7, 7p12, 8q24.12-13, centromere 9, 9p21, centromere 17, 17p13.1, 17q11.2-12, 20q13.2, and centromere Y. Receiver-operator curves were used to determine the sensitivity and specificity of various four-probe combinations for detecting low-grade dysplasia, high-grade dysplasia, and esophageal adenocarcinoma. Endoscopic biopsy results were used as the gold standard. Numerous four-probe combinations provided a similarly high sensitivity and specificity. Of these, a set consisting of probes to 8q24, 9p21, 17q11.2, and 20q13.2 was found to have a sensitivity and specificity, respectively, of 70% and 89% for low-grade dysplasia, 84% and 93% for high-grade dysplasia, and 94% and 93% for esophageal adenocarcinoma. This probe set was chosen for future prospective clinical evaluations based on its high sensitivity and specificity, its ability to distinguish adenocarcinoma and high-grade or low-grade dysplasia from lesser diagnostic categories, and the favorable signal quality for each of the probes.

This article has been cited by other articles:

				A. M. Rygiel, F. Milano, F. J. ten Kate, A. Schaap, K. K. Wang, M. P. Peppelenbosch, J. J.G.H.M. Bergman, and K. K. Krishnadath Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasia-Dysplasia-Adenocarcinoma Sequence of Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1380 - 1385. [Abstract] [Full Text] [PDF]